Our research projects focuses at application in clinic. A small part is preclinical research, but most investment are in clinical phase II like our bladder carcinoma trial. This means our research is being evaluated for therapeutic effect, validation and implementation. Since these are only new medical but not new scientific discoveries, it is hard to obtain sufficient funds for our projects. In the news section you can read more about our latest research progress.

Interleukine-2 (IL-2) was patented in the 1980s (proleukine) and is a registered drug, widely available. Local IL-2 treatment per patients costs approximately 400 euro (300 dollars). Other therapeutics against cancer cost 10.000s to 100.000s euros/dollars. Therefore there is little commercial return on investment to be anticipated for local IL-2 therapy.

We need more money for direct financial support of our researchers and to conduct a clinical phase III study. 

Your financial support is needed to perform these studies:

EPTI Foundation

swift code RABO NL2U

iband nr NL03 RABO 01592 69636


The EPTI foundation is an independent foundation that specifically supports our research.
You can contact us at cancer@kankerimmuuntherapie.nl

---